Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Finance - Asia Logue

China bars millions from travel for 'social credit' offenses

Feb 22, 2019

BEIJING — Forgot to pay a fine in China? Then forget about buying an airline ticket. Would-be air travelers were blocked from buying tickets 17.5 million times last year under a controversial "social credit" system the ruling Communist Party says will improve public behavior. Some 5.5 million people were barred from buying train tickets, according to the National Public Credit Information Center. In an annual report, it said 128 people were blocked from leaving China because they were behind on their taxes. The ruling party says penalties and rewards under "social credit" will improve order in a fast-changing society. Three...

China's new policy against gender bias meets fans, sceptics

Feb 22, 2019

BEIJING — China has announced new measures against gender discrimination in Chinese workplaces that forbid employers from asking potential female hires questions such as if they are married or have children. At some companies in China, the answers to these questions can be disqualifying. Other firms are explicit in their job postings that they are looking only for men. Many welcomed the government notice, published Thursday, which forbids companies and recruitment agencies from taking certain discriminatory actions against female employees and job candidates. But female workers and analysts alike were skeptical that such measures could be strictly enforced. "A notice...

Global stocks mostly rise ahead of US-China tariff war talks

Feb 22, 2019

BEIJING — Most global stock markets rose Thursday as U.S. and Chinese officials entered two days of negotiations aimed at ending a bruising tariff battle. In midday trading in Europe, Britain's FTSE 100 fell 0.7 percent to 7,178 after EU Commission President Jean-Claude Juncker said he remains downbeat on the prospect of Britain avoiding a chaotic exit from the bloc next month. Germany's DAX index advanced 0.4 percent to 11,443 while France's CAC 40 added 0.1 percent to 5,201. On Wall Street, the future for the Standard & Poor's 500 index was roughly unchanged. The future for the Dow Jones...

Report: US company to stop sales of genetic tech in Xinjiang

Feb 22, 2019

BEIJING — Thermo Fisher Scientific Inc. says it will no longer sell or service genetic sequencers in China's mostly Muslim region of Xinjiang following criticism that they were used for surveillance that enabled human rights abuses, The Wall Street Journal reported. The company in Waltham, Massachusetts, cited its "values, ethics code and policies," according to the Journal. The company said it recognized the importance of considering how products "are used — or may be used — by our customers." Thermo Fisher faced criticism from human rights groups and American lawmakers for supplying the equipment used to identify individuals in Xinjiang....

Asian stocks change little ahead of more US-China talks

Feb 22, 2019

BEIJING — Asian stock markets were little-changed Thursday following a listless day on Wall Street ahead of U.S.-Chinese negotiations aimed at ending a tariff battle. Tokyo's Nikkei 225 index lost 0.1 percent to 21,402.69 after a gauge of manufacturing activity fell to a three-year low, suggesting Japanese economic growth is slowing. The Shanghai Composite Index was unchanged at 2,762.67. Sydney's S&P-ASX 200 added 0.4 percent to 6,120.50 while Hong Kong's Hang Seng gained 9 points to 28,526.95. Seoul's Kospi was unchanged at 2,230.15. Benchmarks in New Zealand and Taiwan advanced while Southeast Asian markets mostly declined. Investors looked ahead to...

Sign up now!

Advertisement